OCX
Income statement / Annual
Last year (2023), OncoCyte Corporation's total revenue was $1.50 M,
an increase of 56.89% from the previous year.
In 2023, OncoCyte Corporation's net income was -$27.78 M.
See OncoCyte Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.50 M
|
$958,000.00
|
$7.73 M
|
$1.22 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.09 M |
$976,000.00 |
$7.54 M |
$1.86 M |
$344,000.00 |
$559,000.00 |
$580,000.00 |
$387,000.00 |
$283,000.00 |
$0.00 |
| Gross Profit |
$413,000.00 |
-$18,000.00 |
$188,000.00 |
-$639,000.00 |
-$344,000.00 |
-$559,000.00 |
-$580,000.00 |
-$387,000.00 |
-$283,000.00 |
$0.00 |
| Gross Profit Ratio |
0.27 |
-0.02 |
0.02 |
-0.53 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$9.29 M
|
$7.30 M
|
$13.63 M
|
$9.80 M
|
$6.79 M
|
$6.51 M
|
$7.17 M
|
$5.68 M
|
$4.53 M
|
$3.96 M
|
| General & Administrative
Expenses |
$10.74 M
|
$21.88 M
|
$22.34 M
|
$16.79 M
|
$13.28 M
|
$7.01 M
|
$9.23 M
|
$5.46 M
|
$4.19 M
|
$1.01 M
|
| Selling & Marketing
Expenses |
$2.80 M
|
$1.13 M
|
$11.17 M
|
$6.49 M
|
$2.16 M
|
$1.68 M
|
$2.44 M
|
$1.20 M
|
$324,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.54 M
|
$23.01 M
|
$33.50 M
|
$23.28 M
|
$15.45 M
|
$8.69 M
|
$11.68 M
|
$5.46 M
|
$4.19 M
|
$1.01 M
|
| Other Expenses |
$2.72 M |
-$67,000.00 |
-$37,000.00 |
$27,000.00 |
-$3,000.00 |
$91,000.00 |
$0.00 |
$0.00 |
$2,000.00 |
-$11,000.00 |
| Operating Expenses |
$25.64 M |
$30.31 M |
$47.13 M |
$33.08 M |
$22.24 M |
$15.20 M |
$18.85 M |
$11.14 M |
$8.72 M |
$4.97 M |
| Cost And Expenses |
$26.64 M |
$31.29 M |
$54.67 M |
$34.94 M |
$22.24 M |
$15.20 M |
$18.85 M |
$11.14 M |
$8.72 M |
$4.97 M |
| Interest Income |
$0.00 |
$77,000.00 |
$209,000.00 |
$252,000.00 |
$299,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$52,000.00 |
$77,000.00 |
$209,000.00 |
$252,000.00 |
$299,000.00 |
$216,000.00 |
$217,000.00 |
$28,000.00 |
$19,000.00 |
$2,000.00 |
| Depreciation &
Amortization |
$1.68 M
|
$5.22 M
|
$4.21 M
|
$394,000.00
|
$344,000.00
|
$559,000.00
|
$580,000.00
|
$387,000.00
|
$283,000.00
|
$281,000.00
|
| EBITDA |
-$23.12 M
|
-$13.32 M
|
-$48.46 M
|
-$30.54 M
|
-$21.90 M
|
-$15.20 M
|
-$18.27 M
|
-$11.14 M
|
-$8.44 M
|
-$4.69 M
|
| EBITDA Ratio |
-15.38 |
-31.73 |
-2.18 |
-29.71 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-16.72
|
-18.79
|
-6.08
|
-24.43
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$281,000.00
|
-$615,000.00
|
$854,000.00
|
-$1.48 M
|
-$187,000.00
|
-$552,000.00
|
-$526,000.00
|
-$28,000.00
|
-$17,000.00
|
-$13,000.00
|
| Income Before Tax |
-$24.86 M |
-$18.61 M |
-$73.36 M |
-$31.19 M |
-$22.43 M |
-$15.75 M |
-$19.38 M |
-$11.17 M |
-$8.74 M |
-$4.99 M |
| Income Before Tax Ratio
|
-16.54
|
-19.43
|
-9.49
|
-25.65
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$54.83 M |
-$9.26 M |
-$1.25 M |
-$97,000.00 |
-$336,000.00 |
$217,000.00 |
-$387,000.00 |
-$262,000.00 |
-$9,000.00 |
| Net Income |
-$27.78 M |
-$73.44 M |
-$64.10 M |
-$29.93 M |
-$22.33 M |
-$15.75 M |
-$19.38 M |
-$11.17 M |
-$8.74 M |
-$4.99 M |
| Net Income Ratio |
-18.48 |
-76.66 |
-8.3 |
-24.62 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.75 |
-13.26 |
-14.42 |
-9.14 |
-8.71 |
-8.32 |
-12.83 |
-8.42 |
-8.32 |
-15.36 |
| EPS Diluted |
-3.75 |
-13.26 |
-14.42 |
-9.14 |
-8.71 |
-8.32 |
-12.83 |
-8.42 |
-8.32 |
-15.36 |
| Weighted Average Shares
Out |
$7.65 M
|
$5.54 M
|
$4.45 M
|
$3.27 M
|
$2.56 M
|
$1.89 M
|
$1.51 M
|
$1.33 M
|
$1.05 M
|
$324,615.00
|
| Weighted Average Shares
Out Diluted |
$7.65 M
|
$5.54 M
|
$4.45 M
|
$3.27 M
|
$2.56 M
|
$1.89 M
|
$1.51 M
|
$1.33 M
|
$1.05 M
|
$324,615.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
